Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors
NCT05797168Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2023
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of torvutatug samrotecan in ovarian cancer, lung adenocarcinoma, endometrial cancer (EC), squamous cell carcinoma of the lung (LSCC), solid tumor, sponsored by AstraZeneca. Started Jun 2023; status: recruiting.
02
Drugs
torvutatug samrotecan
03
Conditions
ovarian cancerlung adenocarcinomaendometrial cancer (EC)squamous cell carcinoma of the lung (LSCC)solid tumor
Beyond the preview
Go deeper on NCT05797168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797168.